There are 2789 resources available
998P - Investigating the potential relationship between KRAS mutations and immunotherapeutic biomarkers in lung cancer (LC)
Presenter: Zhengbo Song
Session: ePoster Display
999P - NPC patients with post-RT EBV clearance show a higher frequency of peripheral CD8 T-cells expressing chemo-attractant receptors at baseline and during radiation therapy
Presenter: Shweta Mahajan
Session: ePoster Display
1018P - Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
Presenter: Bartosz Chmielowski
Session: ePoster Display
1019P - Selection of the optimal dose for ALX148, a CD47 blocker, using pharmacokinetic/pharmacodynamic modeling
Presenter: Oleg Demin Jr
Session: ePoster Display
1020P - MPT-0118 a clinical drug candidate to assess Treg reprogramming via MALT1 blockade
Presenter: Peter Keller
Session: ePoster Display
1021P - Long non-coding RNAs influence cancer immunotherapy efficacy through regulating T-cell infiltration and activity or tumor antigenicity
Presenter: Anlin Li
Session: ePoster Display
1034TiP - ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma
Presenter: Richard Carvajal
Session: ePoster Display
1035TiP - A phase I/Ib study of MPT-0118 as monotherapy and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors
Presenter: David Sommerhalder
Session: ePoster Display
Resources:
Abstract
940P - Dose-escalation trial of OBP-301, novel telomerase-specific oncolytic virus in advanced hepatocellular carcinoma
Presenter: Jeong Heo
Session: ePoster Display